Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Clinical trial NCT01933932 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT01933932
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-25
- Primary completion
- 2016-06-07
- Enrollment
- 510
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.